| Literature DB >> 35806490 |
Shuji Mizumoto1, Shuhei Yamada1.
Abstract
The crucial roles of dermatan sulfate (DS) have been demonstrated in tissue development of the cutis, blood vessels, and bone through construction of the extracellular matrix and cell signaling. Although DS classically exerts physiological functions via interaction with collagens, growth factors, and heparin cofactor-II, new functions have been revealed through analyses of human genetic disorders as well as of knockout mice with loss of DS-synthesizing enzymes. Mutations in human genes encoding the epimerase and sulfotransferase responsible for the biosynthesis of DS chains cause connective tissue disorders including spondylodysplastic type Ehlers-Danlos syndrome, characterized by skin hyperextensibility, joint hypermobility, and tissue fragility. DS-deficient mice show perinatal lethality, skin fragility, vascular abnormalities, thoracic kyphosis, myopathy-related phenotypes, acceleration of nerve regeneration, and impairments in self-renewal and proliferation of neural stem cells. These findings suggest that DS is essential for tissue development in addition to the assembly of collagen fibrils in the skin, and that DS-deficient knockout mice can be utilized as models of human genetic disorders that involve impairment of DS biosynthesis. This review highlights a novel role of DS in tissue development studies from the past decade.Entities:
Keywords: Ehlers–Danlos syndrome; biglycan; carbohydrate sulfotransferase 14; chondroitin sulfate; decorin; dermatan 4-O-sulfotransferase; dermatan sulfate; dermatan sulfate epimerase; glycosaminoglycan; proteoglycan
Mesh:
Substances:
Year: 2022 PMID: 35806490 PMCID: PMC9267682 DOI: 10.3390/ijms23137485
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Typical repeating disaccharide units in CS and DS, and their potential sulfation sites. The CS backbone consists of GlcA and GalNAc, whereas DS is a stereoisomer of CS that includes IdoA instead of GlcA. These sugar moieties may be esterified by sulfate at various positions indicated by “SO3–”. The disaccharide units of CS and DS chains are classified as shown. The abbreviation “i” in DS units stands for IdoA, and 2S, 3S, 4S, and 6S stand for 2-O-, 3-O-, 4-O-, and 6-O-sulfate groups, respectively. The representative disaccharide compositions of CS/DS from various tissues and animal species are described in reference [11].
Figure 2Schematic presentation of biosynthesis of the DS chain. All glycosyltransferases require a corresponding UDP-sugar, such as UDP-Xyl, UDP-Gal, UDP-GlcA, and UDP-GalNAc, as a donor substrate. After specific core proteins have been translated, the GAG-protein linker region, GlcA-Gal-Gal-Xyl-, is constructed by XylT, GalT-I, GalT-II, and GlcAT-I. The fifth sugar moiety, GalNAc, is then transferred to the GlcA residue in the linker region by GalNAcT-I, thereby resulting in the formation of the repeating disaccharide region, [-GlcA-GalNAc-]n, which is the unsulfate backbone of CS, by Chn-polymerase that is formed by a hetero complex of any CHSY1, CHSY3, CHPF, or CHPF2. Then, DS-epimerase converts GlcA into IdoA by epimerizing the C-5 carboxy group in the chondroitin precursor, which results in the formation of the repeating disaccharide region of dermatan, [-IdoA-GalNAc-]n. After formation of the dermatan backbone, each sugar residue is modified by sulfation and catalyzed by sulfotransferases, as indicated in the figure. D4ST or UST transfers a sulfate group from PAPS to the C-4 position of the GalNAc or to the C-2 position of the IdoA residues in the dermatan chain, respectively. It should be noted that the 4-O-sulfation but not the 2-O-sulfation is predominant. Each enzyme and its coding gene are described under the respective sugar symbols. The abbreviations 2S and 4S stand for 2-O- and 4-O-sulfates, respectively.
Biological activities of a variety of DS variants.
| DS Origin | Molecular Weight | IdoA Content | Binding Protein(s) | Biological Activities | Reference |
|---|---|---|---|---|---|
| Porcine skin | 11–25 kDa | ~75% | Heparin cofactor II, FGF2, FGF7, collagen | Anti-coagulation, cell growth, assembly of extracellular matrix | [ |
| Ascidian ( | –– | ~100% | Heparin cofactor II | Anti-coagulation, neurite outgrowth-promoting activity | [ |
| Ascidian ( | –– | ~70% | Heparin cofactor II | Anti-coagulation, neurite outgrowth-promoting activity | [ |
| Embryonic sea urcin | –– | ~100% | –– | Neurite outgrowth-promoting activity | [ |
| Hagfish notochord | 18 kDa | 60~75% | FGF2, FGF10, FGF16, FGF18, Midkine, Pleiotrophin, Heparin-binding EGF-like growth factor (HB-EGF), Vascular endothelial growth factor (VEGF), BDNF, GDNF | Neurite outgrowth-promoting activity | [ |
| Shark skin | 70 kDa | 42% | FGF2, FGF10, FGF16, FGF18, Midkine, Pleiotrophin, HB-EGF, VEGF, BDNF, GDNF, heparin cofactor II | Neurite outgrowth-promoting activity, anti-coagulation | [ |
––, not reported.
DS-deficient mice and human disorders.
| Coding Genes | Phenotypes of Knockout or Mutant Mice | Human Genetic Disorders | Ref. for Knockout Mice | Ref. for Human Disorders |
|---|---|---|---|---|
|
| Thicker collagen fibrils in the dermis and hypodermis, smaller body weight, kinked tail, defects in fetal abdominal wall, exencephaly, and spina bifida. | Ehlers–Danlos syndrome musculocontractural type 2 | [ | [ |
|
| Normal extracellular matrix features in the brain. | Bipolar disorder; depressive disorder; diaphragmatic hernia; microphthalmia | [ | [ |
|
| Increased skin fragility, disorganized collagen fibers, thoracic kyphosis, reduced fertility, kinked tail, myopathy-related phenotypes such as variation in fiber size and spread of the muscle interstitium, smaller body mass, alterations in the vascular structure of the placenta, an abnormal structure of the basement membrane of capillaries in the placental villus, better recovery after femoral nerve injury. | Ehlers–Danlos syndrome musculocontractural type 1; Ehlers–Danlos syndrome, type VIB; adducted thumb-clubfoot syndrome | [ | [ |
Alteration of CS/DS disaccharides in the skin fibroblasts from patients with mutations in DSE and CHST14.
| Affected Genes | DS | CS | Reference |
|---|---|---|---|
|
| 9% * | 70% | [ |
|
| Not detected | 189% | [ |
* Compared with the healthy subjects.